Abstract
Direct-acting antiviral (DAA) drugs have been highly effective in the treatment of chronic hepatitis C (CHC) infection. We aim to evaluate the treatment response of Sofosbuvir based DAA in CHC patients with compensated liver cirrhosis as limited data exists in the real-world community setting. All the CHC patients with compensated liver cirrhosis treated with Sofosbuvir based DAAs between January 2014 and December 2017 in a community clinic setting were retrospectively analyzed. Pretreatment baseline patient characteristics, treatment efficacy with the sustained virologic response at 12 weeks posttreatment (SVR12), and adverse reactions were assessed. One hundred and twelve patients with CHC infection and concurrent compensated cirrhosis were included in the study. Black patients represented the majority of the study population (64%). Eighty-seven patients were treated with Ledipasvir/Sofosbuvir (LDV/SOF) ±Ribavirin and 25 patients were treated with Sofosbuvir/Velpatasvir (SOF/VEL). Overall, SVR 12 after treatment was achieved in 90% in patients who received one of the two DAA regimens (89.7% in LDV/SOF group and 92% in SOF/VEL group). SVR 12 did not vary based on age, sex, body mass index, baseline HCV viral load, HCV/HIV coin...Continue Reading
References
May 1, 1997·Journal of Viral Hepatitis·T Poynard, P Bedossa
Dec 2, 1999·Journal of Hepatology·C PiletteP Calès
Jul 4, 2001·Journal of Hepatology·S BrunoM Podda
Jun 24, 2003·The American Journal of Gastroenterology·Shirley A CoverdaleGeoffrey C Farrell
Feb 8, 2006·Journal of Gastroenterology and Hepatology·Hideaki TaniguchiYasushi Shiratori
Apr 14, 2006·Alimentary Pharmacology & Therapeutics·E G Giannini
May 17, 2006·Annals of Internal Medicine·Gregory L ArmstrongMiriam J Alter
Jan 29, 2010·International Journal of Medical Sciences·Nuntra SuwantaratDominic C Chow
Jun 22, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Timothy R MorganUNKNOWN HALT-C Trial Group
Feb 15, 2011·Clinical Therapeutics·Elena VezaliMassimo Colombo
Dec 27, 2012·JAMA : the Journal of the American Medical Association·Adriaan J van der MeerHarry L A Janssen
May 17, 2013·The New England Journal of Medicine·T Jake Liang, Marc G Ghany
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-2 Investigators
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-1 Investigators
Jan 24, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·David R NelsonUNKNOWN ALLY-3 Study Team
Feb 24, 2015·JAMA : the Journal of the American Medical Association·Anu OsinusiShyam Kottilil
Mar 17, 2015·The Lancet Infectious Diseases·Marc BourlièreStanislas Pol
Nov 17, 2015·The New England Journal of Medicine·Jordan J FeldUNKNOWN ASTRAL-1 Investigators
Nov 18, 2015·The New England Journal of Medicine·Graham R FosterUNKNOWN ASTRAL-3 Investigators
Mar 5, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kathleen N LyScott D Holmberg
Apr 10, 2017·Gastroenterology·Ira M JacobsonGraham R Foster
Citations
Oct 28, 2019·Journal of the American Geriatrics Society·Calvin Q PanPavani Garlapati
May 1, 2021·Viruses·Amr Ali HemedaMarwa Ali-Tammam
Dec 1, 2020·European Journal of Gastroenterology & Hepatology·Sameh A LashenAhmed Shaaban